Skip to main content

Bausch + Lomb Corp BLCO-T on Wednesday named Brent Saunders, the former chief executive officer of Allergan, as its CEO and chairman of board, marking his return to the Canadian eye-care company after nearly a decade.

Saunders will join Bausch + Lomb on Feb. 16 in an advisory capacity to help with the transition, the company said.

He will take helm on March 6 from Joseph Papa, who last July announced plans to step down as CEO.

The Vaughan, Ontario-based firm said in December that Papa will continue serving as the CEO until at least March 4, 2023.

Bausch + Lomb is in the process of being spun out from Bausch Health Companies BHC-T, which was formerly known as Valeant Pharmaceuticals.

Saunders has served as the CEO of Botox maker Allergan, until it was acquired by AbbVie Inc for $63-billion in 2020, and previously headed Bausch + Lomb until its acquisition by erstwhile Valeant in 2013.

Report an editorial error

Report a technical issue

Tickers mentioned in this story

Study and track financial data on any traded entity: click to open the full quote page. Data updated as of 10/03/26 4:00pm EDT.

SymbolName% changeLast
BLCO-T
Bausch Lomb Corporation
-0.84%23.53
BHC-T
Bausch Health Companies Inc
+1.1%7.33

Interact with The Globe